Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyTrastuzumab containing regimens for early breast cancerMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesHow Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerTreatment of early-stage HER2+ breast cancer-an evolving fieldSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineA kernelisation approach for multiple d-Hitting Set and its application in optimal multi-drug therapeutic combinationsImproving access to high-cost cancer drugs in Latin America: Much to be done.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Cancer drug related cardiotoxicity during breast cancer treatment.Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Severe thrombocytopenia after trastuzumab retreatment: a case report.Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationTrastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsPertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Prostate cancer and bone: the elective affinities.Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancerERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancerTrastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsOptimizing the management of HER2-positive early breast cancer: the clinical reality.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI studyTherapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.Cancer care delivery in India at the grassroot level: Improve outcomes.Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer.Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialEffectiveness of adjuvant trastuzumab in daily clinical practiceCardiovascular toxicities from systemic breast cancer therapy.Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsPrognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
P2860
Q21284978-6B12A308-BAB0-4AEE-A61A-09F7D7E929FCQ24200192-727DD4DF-ECF5-4714-A218-F8F91DD00834Q26772969-56D07360-7333-49ED-ACF2-A01E31FB3E6FQ26777681-02C2D7A5-8075-4364-8580-0A02AC3FCF31Q26783705-1C7380D1-1868-45C6-BD1B-65097BED2CACQ26824542-58998311-73B6-4782-917B-83C11DA82FB1Q26853619-6D2B9C12-29D4-4EAA-832C-FE4E3C742710Q27011658-05D05C00-DCC0-477A-8AE2-9EF4062ED746Q27025860-3DCF0FCA-ED8C-461F-8016-69FBC5FAB25CQ27025863-680E1E6A-A16C-466E-99D4-E6C92C714705Q28081124-F41A6B9C-D9E7-41C2-B5C7-E68BE96331CDQ28260063-0637A70F-95C2-4E63-B3F9-9D0DA5FF116FQ28475822-63EDAA52-710A-4354-B672-1BD038F78EB4Q30235988-7524D0F1-8E06-4179-9F5A-D58E94C7966AQ30249335-B2BC00D9-0E4A-4A9A-91DF-0D990FBAA1ECQ30251498-2CDB26F4-64A7-49AF-985D-787FC2C1460DQ30371966-73FC68D3-637B-4246-9885-CD39FE807DF8Q33410733-1797B03B-F359-4CF0-BC8D-171C9660734CQ33411110-14803361-E48E-4E50-BCD0-8450AEE6FA09Q33644305-9AD402D4-3167-478E-91E1-C49DADF5E2ECQ33680109-CA84AD07-E14E-4346-A48D-8C70E8E65ED5Q33698446-4207279E-19B0-4E0A-AFC2-F23F34567FDBQ33757791-8783B4F9-D905-4720-9205-35AAB6183998Q33896941-3E8D8ED7-BCFD-47CF-AC8D-FA17EAB2A9A8Q33921374-A2101CA2-AA45-4376-A65A-5CD0443C46F4Q33939795-FEC11EDD-8517-43EB-939E-357AA84F30E6Q34023704-398F31DA-2BC8-42FE-A14A-F33894DFA12EQ34035460-1094EA57-DD47-4D52-89A4-7CEE5D882893Q34240305-6F1185A7-2402-4219-995C-44C8882DD863Q34251780-4140FB67-6DB3-4507-B69D-A2E609FA8382Q34268618-FE68328E-A9CD-456D-9495-1E69B2D1F0F4Q34334333-2F38B8B8-A91B-4F75-A358-E52AD17B9F51Q34344198-2E1239AE-2C5D-440B-8673-BC44951D69BFQ34368263-8C9E27A8-D15F-423A-BC73-D331DEFAE55FQ34427448-EDA516A8-66C5-4D8C-8CF5-32EFFD3C7E4BQ34468964-922124FF-DE3E-4646-A141-F785E661CBA4Q34503912-95320848-3F52-4963-8DBE-C98EF7402031Q34630349-61C303EF-C462-4EAB-A2A9-38A933C22211Q34694605-786AD054-2C74-4576-B46B-7D674D477C64Q35000238-74D48933-2C9C-4642-8909-C9F45B85BA4D
P2860
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@en
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@nl
type
label
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@en
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@nl
prefLabel
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@en
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@nl
P2093
P356
P1476
Fluorouracil, epirubicin, and ...... l results of the FinHer Trial.
@en
P2093
Hannu Leinonen
Jorma Isola
Kari Möykkynen
Leena Helle
Marjo Pajunen
Mauri Huusko
Mika Leinonen
Petri Bono
Pirkko-Liisa Kellokumpu-Lehtinen
Päivi Auvinen
P304
P356
10.1200/JCO.2008.21.4577
P407
P577
2009-11-02T00:00:00Z